Stylus Medicine is developing in vivo genetic medicines using engineered recombinases and targeted, non-viral lipid nanoparticle delivery
Stylus Medicine is developing in vivo genetic medicines using engineered recombinases and targeted, non-viral lipid nanoparticle delivery. Its initial focus is in vivo CAR-T therapies that engineer immune cells inside the body, with potential applications in oncology, autoimmune conditions, and genetic diseases.